JCR Pharmaceuticals Co., Ltd. (4552.T) JPX
615.00
-7(-1.13%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
615.00
-7(-1.13%)
Currency In JPY
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
934
First IPO Date
November 17, 2005
| Name | Title | Pay | Year Born |
| Shin Ashida | Chairman, Chief Executive Officer, President & Chief Operating Officer | 0 | 1943 |
| Hiroshi Yoshimoto | Senior Advisor | 0 | 1951 |
| Katsuya Nishino | Executive Vice President | 0 | 1956 |
| Hiroyuki Fukuya | Director of Legal Affairs Department - Administration Division | 0 | N/A |
| Hiroyuki Sonoda | Senior Managing Executive Officer of Research, Executive Director of Research Division and Director | 0 | 1978 |
| Toshihiro Ishikiriyama | Senior Managing Executive Officer & Executive Director of Business Development Division | 0 | 1952 |
| Yutaka Honda | Senior Executive Officer of Administration & Executive Director of Administration Division | 0 | N/A |
| Ryutaro Makino | Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div. | 0 | N/A |
| Takayo Egawa | Senior Executive Officer & Director of International Affairs | 0 | N/A |
| Toru Ashida | Director, Senior Managing Executive Officer of Sales & Executive Director of Sales Division | 0 | 1968 |
| Yoshihiro Ota | Director of Accounting Department & Corporate Strategy Department (Finance) | 0 | N/A |
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.